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  Sildenafil increases the cyclic guanosine monophosphate 
(cGMP) by inhibition of a  phosphodiesterase  5,  thereby 
leading to an antinociceptive effect. The increased cGMP may 
exert the effect on an L-type calcium channel through the 
activation of protein kinase G (PKG). The purpose of this 
study was to examine the possible involvement of a PKG-L- 
type calcium channel on the effect of sildenafil at the spinal 
level. Catheters were inserted into the intrathecal space of 
male SD rats. Pain was induced by applying 50 μL of a 5% 
formalin solution to the hindpaw. The sildenafil-induced 
effect was examined after an intrathecal pretreatment of a 
PKG  inhibitor  (KT  5823),  or  a  L-type  calcium  channel 
activator (FPL 64176). Intrathecal sildenafil produced an 
antinociceptive effect during phase 1 (0∼10 min interval) and 
phase 2 (10∼60 min interval) in the formalin test. Intrathecal 
KT 5823 and FPL 64176 attenuated the antinociceptive effect 
of sildenafil during both phases. Sildenafil is effective against 
both acute pain and the facilitated pain state at the spinal level. 
In addition, the inhibition of an L-type calcium channel by 
activation of the PKG may contribute to the antinocieptive 
mechanism of sildenafil in the spinal cord.
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Introduction
Cyclic guanosine monophosphate (cGMP) has become 
increasingly important in the understanding of antinociceptive 
mechanisms in the central nervous system [1,13,16,21]. The 
concentration of intracellular cGMP is regulated by the 
action of guanylyl cyclase, as well as by its rate of 
degradation by cGMP-specific phosphodiesterase [2,14]. 
The increased cGMP may activate protein kinase G (PKG), 
which may regulate calcium channels [18]. It has been 
known that calcium ions are widely recognized as having a 
fundamental role in the central nervous system by modulating 
neuronal transduction in the spinal cord [9]. There are four 
types of calcium channels (L-, N-, T- and P-types) in the 
central nervous system [12,19]. These findings suggest that 
the increased cGMP may alter the activity of the calcium 
channels through the activation of PKG, thereby leading to 
a modulation of nociceptive processing. 
Sildenafil (Viagra) is clinically used to treat impotence as 
a cGMP-specific phosphodiesterase 5 inhibitor [4,10] and 
produces antinociception in animal pain model, which is 
mediated through the nitric oxide-cGMP-PKG-potassium 
channel pathway or opioid receptors [1,13,21]. It has been 
recently reported that sildenafil inhibits cerebroarterial 
vasoconstriction by blocking L-type calcium channels [15]. 
Furthermore, the blocking of L-type calcium channels 
produced antinociceptive effects at the spinal level [8,11]. 
The aforementioned findings jointly suggest that activation 
of PKG followed by L-type calcium channel inhibition 
may be involved in the effect of sildenafil. 
Therefore, the aim of this study was to assess the possible 
role of PKG and L-type calcium channels on the activity of 
sildenafil on formalin-induced nociception at the spinal level. 
Materials and Methods
Intrathecal cannulation
This study was approved by The Institutional Animal Care 
Committee, Research Institute of Medical Sciences, Chonnam 
National University. Adult male Sprague-Dawley rats weighing 
250∼300 g were used in all experiments. Rats were allowed 
free access to a standard rat diet and tap water. Room temperature 
was maintained at 20∼23
oC with a 12 : 12 h light/dark cycle. 
Intrathecal catheters (PE-10) were implanted via the cisterna 
magna in enflurane-anesthetized rats [20]. The catheter was 
carefully advanced caudally by 8.5 cm through an incision 
in the atlantooccipital membrane to the lumbar enlargement. 
The exterior part of the catheter was tunneled under the skin, 
externalized on the top of the head, and plugged with a stainless 104    Woong Mo Kim et al.
Fig. 1. Dose response curves of intrathecal sildenafil on the 
flinching response during phase 1 (A) and phase 2 (B) in the 
formalin test. Sildenafil was administered 10 min before the 
formalin injection. Data are presented as the sum of flinches in 
each phase. Sildenafil dose-dependently suppressed the flinches 
during both phases. Each line represents mean ± SE of 6∼8 rats.
Compared with control, *p ＜ 0.05, 
†p ＜ 0.01, 
‡p ＜ 0.001.
steel wire. The skin was closed with 3∼0 silk sutures. Rats 
showing postoperative neurological deficits were killed 
immediately with an overdose of volatile anesthetics. Normal 
rats were kept in individual cages and the formalin test started 
approximately 7 days after intrathecal catheterization. 
Drugs
The following drugs were used in this study: sildenafil 
(Pfizer Korea, Korea), (9S,10R,12R)-2,3,9,10,11,12- 
Hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-
1H-diindolo[1,2,3-fg:3,2,1-kl]pyrrolo[3,4-i][1,6]benzodi
azocine-10-carboxylic acid, methyl ester (KT 5823; Tocris, 
UK), and 2,5-Dimethyl-4-[2-(phentylmethyl)benzoyl]-1H- 
pyrrole-3-carboxylic acid methyl ester (FPL 64176; Tocris, 
UK). Sildenafil and FPL 64176 were dissolved in 20% 
dimethylsulfoxide (DMSO; Sigma-Aldrich, USA), and KT 
5823 was dissolved in normal saline. All the drugs were 
delivered as a 10 μL solution. 
Nociceptive test 
Nociception was induced by subcutaneous injection of 
formalin (5%, 50 μL) into the plantar surface of the rat hind 
paw [21]. Immediately after formalin injection, the rats showed 
a specific nociceptive behavior (flinching), which was 
characterized as a rapid and brief withdrawal or flexing of the 
affected paw. Such pain behavior is quantified by periodically 
counting the number of flinches of the injected paw. The 
flinching response was counted for 60 second periods from 
1 to 2 min and 5 to 6 min, and then at 5 min intervals during 
the interval from 10 to 60 min. As a biphasic flinching response 
was observed after the formalin injection, a 0∼10 min 
interval was defined as phase 1 of the formalin test, whilst 
the interval from 10∼60 min was defined as phase 2. The 
rats were killed using an overdose of volatile anesthetics 
directly after the formalin test to minimize suffering.
Experimental design
The effect of intrathecal sildenafil (1.5, 4.5, 15, 45 nmol/L), 
administered 10 min before the formalin injection, was 
examined. Rats were pretreated with KT 5823 (PKG inhibitor), 
or FPL 64176 (L-type calcium channel activator) to assess 
the involvement of the PKG and L-type calcium channel 
activity on the antinociceptive effect of sildenafil. These two 
drugs were administered intrathecally 10 min before the 
delivery of intrathecal sildenafil (45 nmol/L). The maximum 
doses of KT 5823 (0.02 nmol/L) and FPL 64176 (0.9 nmol/L) 
were selected based on the lack of any significant effect on 
the controlling of the formalin response from the pilot 
experiments of a previous study [1]. The control study was 
performed using intrathecal saline or DMSO depending on 
the solvent for the experimental drug. Animals were 
experimentally naïve and tested only once in this study. In 
total, 88 rats were tested in this study and the number of rats 
per group was 5∼8. The investigator was unaware of the 
drug given to the experimental animals. 
Statistical analysis
Data are expressed as mean ± SE. The dose-response data 
is shown as the sum of the number of flinches in two phases. 
The dose-response data of sildenafil and the antagonism for 
the effect of sildenafil were analyzed by one-way analysis 
of variance with Fisher’s PLSD for the post hoc test, with 
p < 0.05 being considered statistically significant.
Results
Antinociceptive characteristics of intrathecal sildenafil
A subcutaneous injection of formalin into the hindpaw 
resulted in a biphasic flinching response of the injected 
paw. Intrathecal sildenafil, administered 10 min before the 
formalin injection produced a dose-dependent suppression 
of the flinching response during phase 1 and phase 2 in the Spinal sildenafil and PKG-L type calcium channel    105
Fig. 2. The effects of intrathecal KT 5823 (0.02 nmol/L) and FPL
64176 (0.9 nmol/L) on the antinociception effect produced by 
intrathecal sildenafil (45 nmol/L) during phase 1 (A) and phase 2
(B) in the formalin test. KT 5823 and FPL 64176 were administered
10 min before the delivery of sildenafil, and then the formalin test
was done 10 min later. KT 5823 and FPL 64176 reversed the effect
of sildenafil during both phases. Data are presented as the sum of
flinches in each phase. Each bar represents mean ± SE of 5∼6 rats.
Compared with sildenafil, *p ＜ 0.05, 
†p ＜ 0.01.
formalin test (p < 0.05, p < 0.01, p < 0.001; Figs. 1A and B). 
PKG-L-type  calcium  channel  to  the  activity  of 
sildenafil
Neither intrathecal KT 5823 nor FPL 64176 when given 
alone modify the flinching response in control animals at the 
doses used in this study. Intrathecal KT 5823 and FPL 64176 
reversed the antinociceptive effect of intrathecal sildenafil 
in both phases (p < 0.05, p < 0.01; Figs. 2A and 2B). 
Discussion
In the present study, the flinching response decreased in a 
dose-dependent manner both in the first and second phases 
after treatment with intrathecal sildenafil. This observation 
suggests that there is a significant participation of spinal 
phosphodiesterase 5 in the formalin-induced nociception, 
and that the inhibition of this enzyme is effective in 
attenuating the facilitated state pain as well as acute pain in 
the spinal cord. The antinociceptive action of intrathecal 
sildenafil on the formalin-induced nociception was consistent 
with previous findings [1,13,21]. 
Phosphodiesterase enzymes exist extensively in biological 
systems [3]. It is an enzyme involved in the hydrolysis of 
cGMP. Eleven families of phosphodiesterase isoenzymes 
have been identified, all of which have different physical 
characteristics, cellular distribution, and selective sensitivity 
of inhibitors [17]. An in situ hybridization study demonstrated 
the expression of phosphodiesterases 2, 5, and 9 in the spinal 
cord [7]. Among these, types 5, 6, and 9 have specificity 
concerning cGMP hydrolysis, type 5 exerting the most 
significant effects [14]. It has been suggested that cGMP is 
involved in central antinociception. This proposal was 
based on the observation that intrathecal 8-bromo-cGMP 
reduced the mechanical allodynia in neuropathic rats [16]. 
This indicates that the cGMP level might be increased by 
inhibiting this enzyme, thereby producing antinociception. 
Therefore, it is conceivable that sildenafil, a cGMP-specific 
phosphodiesterase 5 inhibitor, may exert an antinociceptive 
effect by inhibiting phosphodiesterase 5 and increasing 
cGMP concentration at the spinal level. 
Here, intrathecal KT 5823 attenuated the antinociceptive 
effect of intrathecal sildenafil, suggesting that the increased 
cGMP by the inhibition of phosphodiesterase 5 may activate 
PKG in the spinal cord, similar to a previous study showing 
that a PKG inhibitor blocked the activity of sildenafil [1]. 
A primary action of elevated cGMP levels is the stimulation 
of cGMP-dependent protein kinase, the major intracellular 
receptor protein for cGMP. The activation of PKG would 
lead to phosphorylation and regulation of ion channels to 
exert its actions [18]. Intrathecal FPL 64176 also reduced the 
antinociceptive effect of sildenafil. These observations 
suggest that sildenafil may exert its antinociceptive effect 
by modulating L-type calcium channels in the spinal cord. 
Calcium ions play an important role in the modulation of 
spinal pain processing [9]. The increase of intracellular calcium 
by means of intrathecal calcium ionophores or calcium 
agonists increased the flinching response to the formalin test 
[6]. Calcium channels are categorized into L-, N-, T- and 
P-types by their electrophysiological characteristics and 
pharmacological sensitivities [12]. Moreover, an 
immunohistochemical study demonstrated the localization 
of these four types of calcium channels in the spinal cord 
[19]. Therefore, it is assumed that the blocking of spinal 
calcium channels may afford antinociception. Indeed, spinal 
L-type calcium channel antagonists produced antinociception 
in an animal model of pain [8,11]. The above-mentioned 106    Woong Mo Kim et al.
findings jointly suggest the PKG-L-type calcium channel is 
sequentially involved in the antinociceptive action of 
sildenafil in the spinal cord. 
Since we have not examined the role of N-, T- and P-type 
calcium channels on the effect of sildenafil in this study, the 
effect antinociceptive mechanisms related to other calcium 
channels on the activity of sildenafil can not be excluded. 
It is known that the modulation of N-, T- and P-type calcium 
channels are also responsible for antinociception. Intrathecal 
N and P-type calcium channel blockers produced antinociception 
[5,8], and cGMP inhibited the activation of N-type calcium 
channels in dorsal root ganglion neurons [22]. However, 
unfortunately, other calcium channel activators have not 
been commercially available. Future studies will be needed 
with selective calcium channels activators to further clarify 
the antinociceptive mechanisms of sildenafil with respect to 
all of the calcium channels.
Seen as a whole, the inhibition of phosphodiesterase 5 by 
sildenafil increases the cGMP levels in the spinal cord, 
which in turn decreases the activity of the L-type calcium 
channel through PKG activation, thereby attenuating the 
facilitated pain state as well as acute pain evoked by the 
formalin injection. 
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